San Diego biotech developing therapies for people living with gout.
| Date | Round | Amount |
|---|---|---|
| Jul 2026 | Series B Crystalys Therapeutics closed an oversubscribed 130 million dollar Series B round led by Frazier Life Sciences to advance its gout treatments. | $130M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.